One To Watch

Cencora

Company Overview

A leading pharmaceutical solutions and drug distribution organization, Cencora operates across wholesale distribution, specialty pharmacy, clinical development support, and oncology services, serving patients and partners globally. Formerly known as AmerisourceBergen, the company rebranded as Cencora in 2023 to reflect its expanded remit beyond traditional wholesale distribution. It is consistently ranked among the largest pharmaceutical companies in the world by revenue. Its services span the full pharmaceutical value chain, from drug development and clinical logistics through to patient-facing specialty care delivery.

Headquarters and Global Presence

Cencora is headquartered in Conshohocken, Pennsylvania. The company maintains a significant European footprint through subsidiaries and logistics operations, most recently expanding its reach with the acquisition of NextPharma Logistics GmbH in October 2025. Its global infrastructure supports pharmaceutical manufacturers, healthcare providers, and patients across multiple continents.

Founding and History

Cencora was formed in 2001 through the merger of AmeriSource and Bergen Brunswig, two major US drug distributors. The combined entity operated as AmerisourceBergen for over two decades before adopting the Cencora name in August 2023. Key strategic moves over the years include the acquisition of specialty logistics provider PharMerica and a long-standing alliance with Walgreens Boots Alliance. The company has steadily shifted its identity from pure-play wholesaler to integrated pharmaceutical solutions partner.

Therapy Areas and Focus

Oncology represents Cencora's most strategic commercial priority, underpinned by its ownership interest in specialty network OneOncology and its longstanding distribution relationships with community oncology practices. The company also has a significant presence in rare diseases and specialty therapeutics, categories characterized by complex logistics, patient support needs, and high-cost biologics. Animal health constitutes a distinct vertical within the business, distinguishing Cencora from most pharmaceutical services peers.

Technology Platforms and Modalities

Cencora does not develop drug candidates but instead operates platform infrastructure that supports pharmaceutical innovation. Its clinical development services arm provides contract research organization capabilities, trial logistics, and regulatory support to drug developers seeking to bring products to market. The company has also built specialized biosimilar tracking and market intelligence tools, including a biosimilars pipeline report that maps all US approvals and launches, reflecting its role as an enabler across the biosimilar adoption cycle.

Key Pipeline and Programs

Cencora does not maintain a proprietary drug pipeline but plays a central enabling role in others' pipelines and launches. Its OneOncology network, valued at $7.4 billion in the December 2025 accelerated buyout, directly links Cencora to the clinical and commercial infrastructure of community oncology practices managing patients enrolled in real-world treatment programs. The company's biosimilars pipeline report tracks 41 approvals and 30 US market launches, and Cencora's distribution channels are a principal conduit through which biosimilar volume flows to providers. On the clinical development side, Cencora's CRO services support Phase I through Phase III trial logistics and drug supply management for biotech and pharma partners. These capabilities position the company as a critical node in the drug development-to-delivery chain rather than an originator of assets.

Recent Developments

In December 2025, Cencora announced it would accelerate its full acquisition of OneOncology by buying out private equity firm TPG's interest in a deal valuing the specialty oncology network at $7.4 billion. In October 2025, the company agreed to acquire NextPharma Logistics GmbH from European CDMO NextPharma, strengthening its European pharmaceutical logistics infrastructure. Together, these two transactions mark a materially more integrated and capital-intensive strategic posture heading into 2026.

Key Personnel

Steven Collis serves as Chairman, President, and Chief Executive Officer of Cencora, having led the organization through its AmerisourceBergen-era strategic acquisitions and the 2023 rebrand. James Cleary serves as Executive Vice President and Chief Financial Officer, overseeing the capital deployment behind major transactions including the OneOncology buyout. Bob Mauch serves as Executive Vice President and Group President, Pharmaceutical Distribution and Strategic Global Sourcing, managing the core wholesale business that underpins group revenues.

Strategic Partnerships

Cencora's most consequential strategic relationship is with Walgreens Boots Alliance, which holds a significant ownership stake in the company and benefits from a long-term drug distribution agreement. The OneOncology acquisition deepens Cencora's integration with one of the largest community oncology networks in the United States. Its European logistics footprint is expanding through acquisitions such as NextPharma Logistics, adding CDMO-adjacent services to the portfolio.

FAQ Section

Cencora is deliberately evolving from a volume-driven drug distributor into an integrated pharmaceutical solutions organization. The $7.4 billion OneOncology acquisition, accelerated in December 2025, is the clearest expression of this shift — embedding the company directly into specialty oncology care delivery. Investments in CRO services, biosimilar infrastructure, and European logistics further reflect the ambition to capture value at multiple points along the pharmaceutical value chain.

Community oncology practices are the primary point of care for the majority of US cancer patients and represent a high-value, high-volume distribution segment for specialty and biologic drugs. Owning OneOncology gives Cencora both distribution pull-through and direct influence over treatment pathways within a network of physician practices. As oncology biosimilars gain market share, having integrated presence in these settings becomes a compounding commercial advantage.

Cencora's differentiation lies in its deeper specialty and services orientation, particularly in oncology through OneOncology and in clinical trial logistics through its CRO capabilities. While all three large US distributors compete on scale and efficiency in core wholesale, Cencora has moved furthest toward owning clinical infrastructure rather than just supplying it. Its animal health vertical and European logistics expansion also offer diversification that peers have not replicated at the same depth.

OneOncology is a specialty practice management network that partners with community oncology physician groups to provide operational, clinical, and technology support. Cencora initially held a minority interest before agreeing in December 2025 to buy out co-investor TPG in a transaction valuing the platform at $7.4 billion. Full ownership gives Cencora direct governance over one of the largest non-hospital oncology networks in the US, with implications for drug purchasing, data, and patient program delivery.

Biosimilars are a structurally important growth driver for Cencora given the company's role as a primary distribution channel for biologics and their lower-cost alternatives. With 41 US biosimilar approvals and 30 launches tracked in Cencora's own pipeline report, the market is maturing rapidly and volume is accelerating. As payers and providers shift formularies toward biosimilars, Cencora's distribution infrastructure and specialty pharmacy capabilities position it to capture a disproportionate share of that flow.

Cencora is in an active consolidation and integration phase, deploying capital at scale to own more of the specialty pharmaceutical care continuum. The OneOncology integration and the digestion of NextPharma Logistics GmbH are the immediate operational priorities heading through 2026. Medium-term milestones include demonstrating earnings accretion from OneOncology, expanding European logistics capabilities, and deepening CRO service revenues as biotech clients seek integrated development-to-distribution partners.

Several watchpoints stand out as Cencora executes its transformation strategy:

OneOncology integration execution — whether the $7.4 billion valuation is validated through physician retention, volume growth, and margin improvement in the network.
Biosimilar penetration rates — accelerating uptake benefits distribution volumes and specialty pharmacy margins, but aggressive price compression could weigh on revenue per unit.
Regulatory and antitrust scrutiny — Cencora's growing market power across distribution, oncology networks, and logistics may attract increased regulatory attention.
Walgreens Boots Alliance relationship — any material change in WBA's ownership stake or distribution contract could affect Cencora's financial profile.
European expansion risk — integrating NextPharma Logistics and scaling in a fragmented European market carries operational complexity and currency exposure.

Want to Update your Company's Profile?